Investors interested in Medical - Drugs stocks are likely familiar with Collegium Pharmaceutical (COLL) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks is more attractive to value investors?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The mean of analysts' price targets for Collegium Pharmaceutical (COLL) points to an 81.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Collegium Pharmaceutical, Inc. ( COLL ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Ian Karp - Head of Investor Relations Vikram Karnani - CEO, President & Director Colleen Tupper - Executive VP & CFO Conference Call Participants Leszek Sulewski - Oppenheimer & Co. Inc., Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Alexander Xenakis - Truist Securities, Inc., Research Division Alexandra von Riesemann - Piper Sandler & Co., Research Division Presentation Operator Greetings, and welcome to the Collegium Pharmaceutical Third Quarter 2026 Earnings Conference Call.
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.96 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $2.25 per share a year ago.
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Collegium Pharmaceutical NASDAQ: COLL reported record third-quarter 2026 revenue as growth in its attention-deficit/hyperactivity disorder portfolio helped offset declining sales of pain medicines. The company reaffirmed its full-year outlook, though quarterly earnings fell from a year earlier.
– Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Generated AZSTARYS ® Quarterly Net Revenue of $26.5 Million in First Full Quarter of Sales Under Collegium Ownership – – Generated Quarterly Pain Portfolio Net Revenues of $138.0 Million – – Announced $50 Million Accelerated Share Repurchase in Q3'26 – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass.
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Collegium Pharmaceutical (COLL) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks offers value investors a better bang for their buck right now?
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.